GWPH GW Pharmaceuticals Plc

115.82
0  0%
Previous Close 116.19
Open 116.69
Price To book 6.10
Market Cap 2.92B
Shares 25,225,000
Volume 199,372
Short Ratio 6.03
Av. Daily Volume 319,248

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 trials to be initiated 2H 2017.
GWP42006 (CBDV)
Autism
Phase 3 initiated December 2016.
Epidiolex
Infantile spasms (IS)
Phase 2 data released September 2015. Currently evaluating next steps
GWP42003
Schizophrenia
Phase 2 trial did not meet endpoint
GWP42004
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Sativex
Cancer pain
Phase 2 initiated May 2015. Data due 2H 2017.
GWP42006 (CBDV)
Epilepsy
Second Phase 3 trial initiated mid April 2015. Data due 2017.
Epidiolex
Dravet Syndrome
Top line Phase 3 data released March 2016 met primary endpoint. NDA Filing due mid-2017.
Epidiolex
Dravet Syndrome
First Phase 3 trial data released June 2016. Data from second Phase 3 trial also met endpoint - September 2016. NDA filing due mid 2017.
Epidiolex
Lennox-Gastaut syndrome (LGS)
Phase 3 trial ongoing as of February 7, 2017.
Epidiolex
Tuberous Sclerosis Complex
Phase 2 trial did not meet primary endpoint - noted February 7, 2017.
Sativex
Spasticity due to cerebral palsy

Latest News

  1. Better Know a Marijuana Stock: Insys Therapeutics
  2. Op-Ed: The US is falling behind other countries—like Canada—on marijuana
  3. 2 New Ways To Invest In Marijuana Stocks: Cannabis ETFs
  4. This Unknown Marijuana Stock Could Return 400% in 2017
  5. Top 4 Medicinal Marijuana Stocks to Watch for 2017
  6. GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released by the American Academy of Neurology
  7. GreenWave's Matt Karnes Talks About Cannabis Banking, Tax Burdens And Stocks To Watch
  8. 5 Stocks To Profit From The Canadian Marijuana Boom
  9. GreenWave's Matt Karnes Predicts Fully Legal Cannabis Markets In 8 New States By 2018
  10. Yikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016
  11. 3 Marijuana Stocks You Can Still Buy Without (Too Much) Fear
  12. Better Know a Marijuana Stock: GW Pharmaceuticals
  13. GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) at the 2017 American Academy of Neurology Annual Meeting
  14. 5 Drug-Developing Marijuana Stocks You Need to Know
  15. 3 Marijuana Stocks to Buy if You're Leery of Buying Marijuana Stocks
  16. The Very First Marijuana Stock ETF Just Debuted -- Should You Be Buying?
  17. Gottlieb Should Consider Cannabis As He Makes Opioids His Top Priority
  18. Play the Marijuana Rush as First Marijuana-Focused ETF Launches
  19. 2 Marijuana Stocks That Turned $10,000 Into Over $130,000
  20. Collect Smokin' Hot Profits From This Marijuana Biotech